- Conditions
- Adult Solid Neoplasm
- Interventions
- Computed Tomography, Imaging Phantoms, Positron Emission Tomography
- Procedure · Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 1,219
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Tafasitamab, Tazemetostat, Zanubrutinib
- Procedure · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 104
- States / cities
- Tucson, Arizona • Beverly Hills, California • Duarte, California + 81 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 50
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Healthy
- Interventions
- FDG, Ketone Drink, Ketogenetic Diet
- Drug · Dietary Supplement · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diagnostic Imaging
- Interventions
- BAY1075553
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Drug
- Lead sponsor
- Sanjiv Sam Gambhir
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
- Interventions
- Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
- Conditions
- CTE, TBI (Traumatic Brain Injury)
- Interventions
- [F-18]FDDNP
- Radiation
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Electronic health record review, Medical Device Usage and Evaluation, Physical functions assessments, Positron Emission Tomography (PET), Survey Administration
- Procedure · Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Enzalutamide, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Tafasitamab, Venetoclax
- Procedure · Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Melanoma, Neuroblastoma, Sarcoma
- Interventions
- 124I-Humanized 3F8
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 90 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Liver Carcinoma, Liver Cirrhosis
- Interventions
- 18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Breast Cancer, Brain Metastases
- Interventions
- Brain Imaging with 18F-FES
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Interventions
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Leukemia, Lymphoma
- Interventions
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Head and Neck Cancer
- Interventions
- Intensity Modulated Radiation Therapy
- Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Encinitas, California • Irvine, California • La Jolla, California + 12 more
- Conditions
- Prostate Cancer
- Interventions
- [89Zr]Df-IAB2M
- Radiation
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Breast Cancer, Stage IV Breast Cancer
- Interventions
- positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Solid Malignancy, Lymphoma
- Interventions
- [18F] 4-L-Fluoroglutamine (2S,4R)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancers
- Interventions
- anti [18F]FACBC
- Drug
- Lead sponsor
- David M. Schuster, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia